Fusion to Human Serum Albumin Extends the Circulatory Half-Life and Duration of Antithrombotic Action of the Kunitz Protease Inhibitor Domain of Protease Nexin 2 | Zendy

William P. Sheffield | Zendy; Louise J. EltringhamSmith | Zendy; Varsha Bhakta | Zendy

Open Access

Fusion to Human Serum Albumin Extends the Circulatory Half-Life and Duration of Antithrombotic Action of the Kunitz Protease Inhibitor Domain of Protease Nexin 2

Author(s) -

William P. Sheffield,

Louise J. EltringhamSmith,

Varsha Bhakta

Publication year - 2018

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000487168

Subject(s) - protease , protease inhibitor (pharmacology) , antithrombotic , circulatory system , proteases , albumin , biology , chemistry , pharmacology , medicine , immunology , biochemistry , enzyme , endocrinology , virus , viral load , antiretroviral therapy

The Kunitz Protease Inhibitor (KPI) domain of protease nexin 2 (PN2) potently inhibits coagulation factor XIa. Recombinant KPI has been shown to inhibit thrombosis in mouse models, but its clearance from the murine circulation remains uncharacterized. The present study explored the pharmacokinetic and pharmacodynamic effects of fusing KPI to human serum albumin (HSA) in fusion protein KPIHSA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research